Ptc Therapeutics Stock Analysis
PTCT Stock | USD 57.14 0.51 0.90% |
PTC Therapeutics is undervalued with Real Value of 60.66 and Target Price of 58.36. The main objective of PTC Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what PTC Therapeutics is worth, separate from its market price. There are two main types of PTC Therapeutics' stock analysis: fundamental analysis and technical analysis.
The PTC Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. PTC Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. PTC Stock trading window is adjusted to America/New York timezone.
PTC |
PTC Stock Analysis Notes
About 100.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.81. PTC Therapeutics recorded a loss per share of 4.73. The entity had not issued any dividends in recent years. PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. Ptc Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people. To find out more about PTC Therapeutics contact Stuart Peltz at 908 222 7000 or learn more at https://www.ptcbio.com.PTC Therapeutics Quarterly Total Revenue |
|
PTC Therapeutics Investment Alerts
The company reported the previous year's revenue of 806.78 M. Net Loss for the year was (363.3 M) with profit before overhead, payroll, taxes, and interest of 214.9 M. | |
PTC Therapeutics currently holds about 288.43 M in cash with (107.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.01. | |
Over 100.0% of the company shares are owned by institutional investors | |
Latest headline from gurufocus.com: PTC Therapeutics Unveils Promising Sepiapterin Data from Phase 3 APHENITY Trial |
PTC Therapeutics Upcoming and Recent Events
20th of February 2024 Upcoming Quarterly Report | View | |
25th of April 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
20th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
PTC Largest EPS Surprises
Earnings surprises can significantly impact PTC Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2018-08-07 | 2018-06-30 | -0.29 | -0.21 | 0.08 | 27 | ||
2013-11-14 | 2013-09-30 | -0.3 | -0.19 | 0.11 | 36 | ||
2015-11-09 | 2015-09-30 | -1.15 | -1.27 | -0.12 | 10 |
PTC Therapeutics Environmental, Social, and Governance (ESG) Scores
PTC Therapeutics' ESG score is a quantitative measure that evaluates PTC Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of PTC Therapeutics' operations that may have significant financial implications and affect PTC Therapeutics' stock price as well as guide investors towards more socially responsible investments.
PTC Therapeutics Thematic Classifications
In addition to having PTC Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
![]() | Cancer FightersPublic companies from health care and pharmaceutical sectors that are focused on fighting cancer |
PTC Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | D. E. Shaw & Co Lp | 2024-12-31 | 1.5 M | Point72 Asset Management, L.p. | 2024-12-31 | 1.4 M | Franklin Resources Inc | 2024-12-31 | 1.3 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.1 M | Ubs Group Ag | 2024-12-31 | 1.1 M | Blackstone Inc | 2024-12-31 | 1.1 M | Driehaus Capital Management Llc | 2024-12-31 | 1 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 826.5 K | Vanguard Group Inc | 2024-12-31 | 9.2 M | Blackrock Inc | 2024-12-31 | 7.9 M |
PTC Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.51 B.PTC Profitablity
The company has Profit Margin (PM) of (0.45) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.07.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.24) | (0.25) | |
Return On Capital Employed | (0.27) | (0.26) | |
Return On Assets | (0.21) | (0.22) | |
Return On Equity | 0.33 | 0.35 |
Management Efficiency
PTC Therapeutics has return on total asset (ROA) of (0.0509) % which means that it has lost $0.0509 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (77.4012) %, meaning that it created substantial loss on money invested by shareholders. PTC Therapeutics' management efficiency ratios could be used to measure how well PTC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.35 in 2025, whereas Return On Tangible Assets are likely to drop (0.25) in 2025. At this time, PTC Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 2.3 B in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1.1 B in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | (14.29) | (13.57) | |
Tangible Book Value Per Share | (16.91) | (16.06) | |
Enterprise Value Over EBITDA | (25.55) | (24.28) | |
Price Book Value Ratio | (3.16) | (3.00) | |
Enterprise Value Multiple | (25.55) | (24.28) | |
Price Fair Value | (3.16) | (3.00) | |
Enterprise Value | 3.1 B | 3.2 B |
PTC Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Technical Drivers
As of the 23rd of March, PTC Therapeutics owns the semi deviation of 1.94, and Market Risk Adjusted Performance of 0.3488. In relation to fundamental indicators, the technical analysis model allows you to check practical technical drivers of PTC Therapeutics, as well as the relationship between them.PTC Therapeutics Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. PTC Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for PTC Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
PTC Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PTC Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on PTC Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases PTC Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
PTC Therapeutics Outstanding Bonds
PTC Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. PTC Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PTC bonds can be classified according to their maturity, which is the date when PTC Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
PSI ENERGY INC Corp BondUS693627AY70 | View | |
US693656AC47 Corp BondUS693656AC47 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
PTC Therapeutics Predictive Daily Indicators
PTC Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of PTC Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
PTC Therapeutics Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 17th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 14th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 12th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 6th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 21st of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
14th of February 2025 Other Reports | ViewVerify |
PTC Therapeutics Forecast Models
PTC Therapeutics' time-series forecasting models are one of many PTC Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary PTC Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About PTC Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how PTC Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling PTC shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as PTC Therapeutics. By using and applying PTC Stock analysis, traders can create a robust methodology for identifying PTC entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.45) | (0.47) | |
Operating Profit Margin | (0.38) | (0.39) | |
Net Loss | (0.45) | (0.47) | |
Gross Profit Margin | 0.84 | 0.88 |
Current PTC Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. PTC analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. PTC analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
58.36 | Buy | 15 | Odds |
Most PTC analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand PTC stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of PTC Therapeutics, talking to its executives and customers, or listening to PTC conference calls.
PTC Stock Analysis Indicators
PTC Therapeutics stock analysis indicators help investors evaluate how PTC Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading PTC Therapeutics shares will generate the highest return on investment. By understating and applying PTC Therapeutics stock analysis, traders can identify PTC Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 610.3 M | |
Long Term Debt | 2.1 B | |
Common Stock Shares Outstanding | 76.8 M | |
Total Stockholder Equity | -1.1 B | |
Tax Provision | 176 K | |
Property Plant And Equipment Net | 117.7 M | |
Cash And Short Term Investments | 1.1 B | |
Cash | 779.7 M | |
Accounts Payable | 17.3 M | |
Net Debt | -390.4 M | |
50 Day M A | 49.649 | |
Total Current Liabilities | 581 M | |
Other Operating Expenses | 1.1 B | |
Non Current Assets Total | 339.5 M | |
Forward Price Earnings | 21.3675 | |
Non Currrent Assets Other | 20.7 M | |
Stock Based Compensation | 74.6 M |
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.